ADVENZYMES Advanced Enzyme Technologies Q2 FY27 results (Jul–Sep 2026) and concall
Advanced Enzymes grew revenue 16% YoY to ₹214.5 crores in Q2 FY27, with growth in all four segments, led by Bio-Processing (+43%) and Animal Healthcare (+37%). EBITDA margin rose to 34% thanks to operating efficiencies despite elevated input costs, and PAT grew 14% to ₹51.2 crores. Management guided only to 30-32% EBITDA margins and lower double-digit growth. They said the US nutrition market is showing early signs of a turnaround, possibly within 1-2 quarters, but Evoxx and US clients remain weak. Capital allocation included a completed open-market buyback, about ₹610 crores of cash, and an u
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY27: revenue down 38.5%, net profit up 13.3% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 6 | 20 | 26 | 2 −60% | 22 +267% | 3 −85% | 16 −38% |
| EBITDA | 55 | 46 | 56 | 60 | 49 −11% | 63 +37% | 53 −5% | 72 +20% |
| Net profit | 39 | 27 | 40 | 45 | 43 +10% | 45 +67% | 39 −2% | 51 +13% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
